Table 1 Sample characteristics (N = 54).

From: The enhancing effects of testosterone in exposure treatment for social anxiety disorder: a randomized proof-of-concept trial

 

Total sample

(N = 54) Mean (SD)

Placebo

(n = 27), Mean (SD)

Testosterone

(n = 27) Mean (SD)

t or χ2, p

Demographics

Age

23.31 (5.64)

24.00 (6.85)

22.61 (4.12)

0.90, 0.372

SPS total score

30.20 (11.85)

32.15 (13.82)

28.26 (9.35)

1.21, 0.232

LSAS total score

63.06 (19.24)

64.70 (18.96)

61.41 (19.73)

0.62, 0.534

Initial SUD score

20.59 (13.86)

20.44 (11.33)

20.74 (16.21)

0.77, 0.938

Testosterone sample 1

15.17 (16.41)

15.94 (19.65)

15.47 (12.76)

0.105, 0.917

Testosterone sample 2

16.21 (15.45)

17.57 (16.83)

14.80 (14.06)

0.650, 0.518

Testosterone sample 3

252.49 (380.03)

15.29 (16.19)

489.68 (421.06)

−5.85, <0.001

Educational level (n)

   

1.15, 0.680

 High school

7

2

5

 

 Intermediate vocational

6

3

3

 

 Higher vocational

11

6

5

 

 University

30

16

14

 

Psychological treatment (n)

9

5

4

0.13, 0.715

Psychotropic medication use (n)

4

2

2

2.00, 0.572

Contraceptive use (n)

   

1.29, 0.733

 Hormonal

30

15

15

 

 Non-hormonal

24

12

12

0.00, 1.00

Comorbid anxiety disorder (n)

18

11

7

1.39, 0.239

Comorbid depressive disorder (n)

5

2

3

0.22, 0.639

Participants believed to be in T group (n)

12

7

5

 
  1. For testosterone sample 2 in the testosterone group, n = 26 as one participant had a missing value. Testosterone values are in picograms per milliliter (pg/ml). (n) = values are expressed as number of participants.
  2. SPS Social Phobia Scale, LSAS Liebowitz Social Anxiety Scale, SUD subjective units of distress.